Filing Overview
Registrant: Tivic Health Systems, Inc. (Nasdaq: TIVC). The request metadata identifies Valion Bio, Inc., but the filing text names Tivic Health Systems, Inc. This Form 8-K was filed June 9, 2023 regarding events at the June 6, 2023 annual meeting of stockholders.
Business Context and Reporting Period
The filing reports the partial conduct and adjournment of the Company’s 2023 Annual Meeting. As of the April 13, 2023 record date, 29,677,734 common shares were outstanding. Holders of 15,223,926 shares, approximately 51.3% of the outstanding shares, were represented in person or by proxy, establishing a quorum.
Financial and Operating Metrics
This 8-K does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating or financial-period metrics. It is primarily a shareholder-vote and corporate-governance filing.
Material Changes and Meeting Results
- The Company adjourned the meeting because it had difficulty securing votes from a significant number of stockholders.
- The only proposal voted on at the June 6 meeting was authorization to adjourn. It was approved with 14,272,410 votes for, 897,725 against, and 53,791 abstentions; there were no broker non-votes.
- Proposals not voted on at the June 6 meeting were: election of one Class II director; authorization for a reverse stock split between 1-for-5 and 1-for-30, at the Board’s discretion within 12 months; and ratification of Rosenberg Rich Baker Berman, P.A. as independent registered public accounting firm for the year ending December 31, 2023.
- The meeting was reconvened for June 14, 2023, at 1:00 p.m. Pacific Time, via the Internet. Record-date stockholders remained entitled to vote on the pending proposals.
Guidance, Risks, and Unusual Items
No financial guidance or business outlook was provided. The proposed reverse stock split represents a material potential capital-structure change, but approval and the final ratio were pending as of this filing. The filing includes customary forward-looking-statement risk language stating that actual results may differ materially because of known and unknown risks and uncertainties.
Investor Verification Checklist
- Confirm the issuer identity: the filing is for Tivic Health Systems, Inc., not Valion Bio, Inc.
- Verify the subsequent outcome of the June 14, 2023 reconvened meeting, including the director election, reverse-stock-split proposal, and auditor ratification.
- Determine whether a reverse stock split was ultimately approved, its ratio, and its implementation date.
- Review subsequent filings for any effects on share count, Nasdaq listing compliance, financing needs, liquidity, or dilution.
- Confirm that the meeting vote totals and record-date share count agree with later proxy or Form 8-K disclosures.